Eli Lilly and Company today announced positive topline results from the landmark TOGETHER-PsO open-label Phase 3b clinical trial evaluating the concomitant use of Taltz (ixekizumab) and Zepbound ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results